Chronic pain (CP) is a severe clinical entity with devastating physical and emotional consequences for patients, which can occur in a myriad of diseases. Often, conventional treatment approaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, produced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can modulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP.

Endocrine and Metabolic Diseases Research Center School of Medicine University of Zulia Maracaibo 4004 Venezuela

Escuela de Nutrición y Dietética Facultad de Medicina Universidad Andres Bello Santiago 8370035 Chile

Facultad de Ciencias de la Salud Universidad Simón Bolívar Barranquilla 080002 Colombia

Institute of Molecular and Translational Medicine Palacký University Olomouc 77900 Olomouc Czech Republic

Programa de Psicología Fundación Universitaria del Área Andina sede Valledupar Valledupar 200001 Colombia

000      

00000naa a2200000 a 4500

001      

bmc22003672

003      

CZ-PrNML

005      

20220127150006.0

007      

ta

008      

220113s2021 sz f 000 0|eng||

009      

AR

024    7_

$a 10.3390/ijms221910370 $2 doi

035    __

$a (PubMed)34638711

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a sz

100    1_

$a Chávez-Castillo, Mervin $u Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela

245    10

$a Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy / $c M. Chávez-Castillo, Á. Ortega, L. Cudris-Torres, P. Duran, M. Rojas, A. Manzano, B. Garrido, J. Salazar, A. Silva, DM. Rojas-Gomez, JB. De Sanctis, V. Bermúdez

520    9_

$a Chronic pain (CP) is a severe clinical entity with devastating physical and emotional consequences for patients, which can occur in a myriad of diseases. Often, conventional treatment approaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, produced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can modulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP.

650    _2

$a zvířata $7 D000818

650    _2

$a chronická bolest $x metabolismus $x terapie $7 D059350

650    _2

$a kyseliny mastné omega-3 $x metabolismus $7 D015525

650    _2

$a kyseliny mastné omega-6 $x metabolismus $7 D043371

650    _2

$a lidé $7 D006801

650    _2

$a mediátory zánětu $x metabolismus $7 D018836

650    12

$a management bolesti $7 D059408

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

700    1_

$a Ortega, Ángel $u Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela

700    1_

$a Cudris-Torres, Lorena $u Programa de Psicología, Fundación Universitaria del Área Andina sede Valledupar, Valledupar 200001, Colombia

700    1_

$a Duran, Pablo $u Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela

700    1_

$a Rojas, Milagros $u Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela

700    1_

$a Manzano, Alexander $u Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela

700    1_

$a Garrido, Bermary $u Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela

700    1_

$a Salazar, Juan $u Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela

700    1_

$a Silva, Aljadis $u Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4004, Venezuela

700    1_

$a Rojas-Gomez, Diana Marcela $u Escuela de Nutrición y Dietética, Facultad de Medicina, Universidad Andres Bello, Santiago 8370035, Chile

700    1_

$a De Sanctis, Juan B $u Institute of Molecular and Translational Medicine, Palacký University Olomouc, 77900 Olomouc, Czech Republic

700    1_

$a Bermúdez, Valmore $u Facultad de Ciencias de la Salud, Universidad Simón Bolívar, Barranquilla 080002, Colombia

773    0_

$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 19 (2021)

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34638711 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220113 $b ABA008

991    __

$a 20220127150002 $b ABA008

999    __

$a ok $b bmc $g 1751205 $s 1154821

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 22 $c 19 $e 20210926 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142

GRA    __

$a CC-0437-10-21-09-10 $p Consejo de Desarrollo Científico, Humanístico y Tecnológico, Universidad del Zulia

LZP    __

$a Pubmed-20220113